Advancing treatments for higher-risk MDS has remained an unsolved mystery for far too long
Therapeutic advancement in higher-risk myelodysplastic syndrome ( MDS ) has been stagnant , leaving patients and physicians ill-equipped for many years . 1 , 2 There is an urgent need for more effective treatments for higher-risk MDS that modify the underlying disease biology , ideally to improve patient outcomes , such as response rates , delayed transformation to AML , and survival . 3
New pathways that target the underlying disease have the potential to break the case against higher-risk MDS wide open . Gilead Sciences is committed to researching innovative therapies for patients with MDS and the healthcare professionals who treat them .
References : 1 . Steensma DP . Myelodysplastic syndromes current treatment algorithm 2018 . Blood Cancer J . 2018 ; 8 ( 5 ): 47 . 2 . Platzbecker U . Treatment of MDS . Blood . 2019 ; 133 ( 10 ): 1096-1107 . 3 . Scalzulli E , Pepe S , Colafigli G , Breccia M . Therapeutic strategies in low and high-risk MDS : what does the future have to offer ? Blood Rev . 2021 ; 45 ( 100689 ): 1-9 .
© 2021 Gilead Sciences , Inc . All rights reserved . UNBP6538 06 / 21
13